期刊文献+

不同分子亚型乳腺癌超声及MRI特征 被引量:12

Ultrasonic and MRI features of breast cancers of different molecular subtypes
下载PDF
导出
摘要 目的探讨不同分子亚型乳腺癌超声和MRI表现。方法回顾性分析101例经病理证实的乳腺癌患者(109个病灶)的超声和MRI资料;根据雌激素受体、孕激素受体、人表皮生长因子受体-2(HER-2)的表达状态,将乳腺癌分为三阴性、HER-2过表达和Luminal三个亚型,分析不同亚型乳腺癌超声和MRI表现。结果三种分子亚型乳腺癌病理分型差异有统计学意义(P<0.05);超声声像图中不同分子亚型乳腺癌的边界、边缘、是否钙化、血供程度及周围组织结构变化差异有统计学意义(P均<0.05);MRI中不同分子亚型乳腺癌平扫信号、边界、边缘、强化与否及强化方式和时间-信号强度曲线类型差异有统计学意义(P均<0.05)。结论不同分子亚型乳腺癌超声及MRI表现各具特点。 Objective To investigate the ultrasonic and MRI features of breast cancers of different molecular subtypes. Methods Ultrasonic and MRI data of 101 patients (109 lesions) with breast cancer confirmed by pathology were retrospectively analyzed. According to the expression of estrogen receptors, progesterone receptor and human epidermal growth factor receptor-2 (HER-2), the tumors were classified into triple-negative, HER-2 over-expressed and Luminal subtypes. The ultrasonic and MRI features of breast cancers of different molecular subtypes were compared. Results There were statistical differences in pathological type among different molecular subtype breast cancers (P〈0.05). The border, calcification, blood supply of tumor and the changes of surrounding tissue of tumors in ultrasonography, the signal intensity, border, intensify and time-signal intensity curve type in MRI were statistically different among breast cancer of different molecular subtypes (all P〈0.05). Conclusion Ultrasonic and MRI features of different molecular subtypes breast cancers are different.
出处 《中国医学影像技术》 CSCD 北大核心 2013年第8期1297-1300,共4页 Chinese Journal of Medical Imaging Technology
关键词 乳腺肿瘤 超声检查 磁共振成像 免疫组织化学 Breast neoplasms Ultrasonography Magnetic resonance imaging Immunohistochemitry
  • 相关文献

参考文献13

  • 1Zheng G, Peng F, Ding R, et al. Identification of proteins re- sponsible for the multiple drug resistance in 5-fluorouracil-induced breast Cancer cell using proteomics analysis. J Cancer Res Clin Oncol, 2010,136(10) : 1477-1488.
  • 2Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N EnglJ Med, 2010,363(20):1938-1948.
  • 3Lin NU, Vanderplas A, Hughes ME, et al. Clinicopathologic features, patterns of recurrence, and survival among women with triple-negative breast cancer in the National Comprehensive Canc- er Network. Cancer, 2012,118(22):5463-5472.
  • 4Sawaki M, Ito Y, Tada K, et al. Efficacy and safety of trastu- zumab as a single agent in heavily pretreated patients with HER- 2/neu-overexpressing metastatic breast cancer. Tumori, 2004,90 (1) :40-43.
  • 5Munjal K, Ambaye A, Evans MF, et al. Immunohistochemieal analysis of ER, PR, HER-2 and CK5/6 in infiltrative breast car- cinomas in Indian patients. Asian Pac J Cancer Prev, 2009, 10 (5) :773-778.
  • 6Wo]einski S, Soliman AA, Sehmidt J, et al. Sonographic features of triple-negative and non-triple-negative breast cancer. J Ultra- sound Med, 2012,31(10) : 1531-1541.
  • 7Karamouzis MV, Likaki-Karatza E, Ravazoula P, et al. Non-pal- pable breast carcinomas : Correlation of mammographically detec- ted malignant-appearing microcalcifications and molecular prog- nostic factors. Int J Cancer, 2002, 102(1) :86-90.
  • 8Seo BK, Pisano ED, Kuzimak CM, et al. Correlation o: HER-2/ neu overexpression with mammography and age distribution in primary breast carcinomas. Acad Radiol, 2006, 13(10): 1211 1218.
  • 9Rakha EA, E1-Rehim DA, Paish C, et al. Basal phenotype iden- tifies a poor prognostic subgroup of breast cancer of clinical im- portance. Eur J Cancer, 2006,42(18):3149-3156.
  • 10Haupt B, Ro JY, Schwartz MR. Basal-like breast carcinoma: A phenotypically distinct entity. Arch Pathol Lab Med, 2010, 134 (1) :130-133.

同被引文献126

  • 1陈蓉,龚水根,张伟国,陈金华,何双梧,刘宝华,李增鹏.乳腺癌MRI形态学表现与病理、分子生物学相关性研究[J].中华放射学杂志,2004,38(6):620-625. 被引量:55
  • 2<乳腺癌HER2检测指南>编写组,霍临明.乳腺癌HER2检测指南[J].中华病理学杂志,2006,35(10):631-633. 被引量:164
  • 3Teifke A, Hlawatsch A, Beier T, et al. Undetected malignancies of the breast: Dynamic contrast-enhanced MR imaging at 1.0T. Radiology, 2002,224(3) : 881-888.
  • 4La Trenta LR, Mcneil JH, Morris EA, et al. Breast lesions de- tected with MR imaging: Utility and histopathologic importance of identification with US. Radiology, 2003,227(3) :856-861.
  • 5International Human Genome Sequencing Consortium. Finishing the euchromatic sequence of the human genome. Nature, 2004, 431(7011) :931-945.
  • 6Onitilo AA, Engel JM, Greenlee RT, et al. Breast cancer sub- types based on ER/PR and Her2 expression: Comparison of clini- copathologic features and survival. Clin Med Res, 2009,7 (1-2):4-13.
  • 7Kennecke H, Yerushalmi R, Woods R, et al. Metastatic behav- ior of breast cancer subtypes. J Clin Oncol, 2010,28(20) : 3271- 3277.
  • 8Haffty BG, Yang Q, Reiss M, et al. Locoregional relapse and distant metastasis in conservatively managed triple negative early- stage breast cancer. J Clin Oncol, 2006,24(36):5652-5657.
  • 9Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adju- vant hemotherapy for operable HER2-positive breast cancer. N Engl Jed, 2005,353(16) :1673-1684.
  • 10Perez EA, Romond EH, Suman VJ, et al. Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epi- dermal growth factor receptor 2 positive breast cancer: Joint anal- ysis of data from NCCTG N9831 and NSABP B-31. J Clin Oncol, 2011,29(25) : 3366-3373.

引证文献12

二级引证文献94

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部